Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion

Part of paid clinical trials in Beverly Hills, California.

Sponsor
Peter A Campochiaro, MD
Study ID
NCT01198327
Phase
PHASE3
Status
Completed

Conditions

  • Retinal Vein Occlusion

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ranibizumab — DRUG
    Intravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart.
  • Peripheral Laser — OTHER
    Areas of nonperfusion identified on wide field angiograms will receive laser, if the patient is continuing to require ranibizumab injections.

Study Details

This study evaluates long-term safety in patients with macular edema due to Retinal Vein Occlusion (RVO) originally enrolled in the BRAVO \& CRUISE trials and subsequently followed in the HORIZON extension trial.

Key Dates

First listed
Sep 10, 2010
Start date
Aug 31, 2010
Status verified
Nov 2013
Primary completion
Dec 31, 2012
Completion
Dec 31, 2012

Study Design

Enrollment
66 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ranibizumab as needed
    Intravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart; with optional peripheral laser to areas of non-perfusion.

Primary Outcome Measure

Incidence of Serious Adverse Events. [ Time Frame: 24 mos ]

Locations (6)

FacilityCityStateZIPSite coordinators
Retina-Vitreous Associates Medical GroupBeverly HillsCalifornia90211-
Retinal Consultants Medical GroupSacrementoCalifornia95819-
Southeast RetinaAugustaGeorgia30909-
Ophthalmic consultants of BostonBostonMassachusetts02114-2587-
Retina Associates of New JerseyTeaneckNew Jersey07666-
Retina Consultants of HoustonHoustonTexas77030-

Find similar trials in Beverly Hills, CA

Related Studies